LEVETIRACETAM TEVA ® 250 MG

Country: Իսրայել

language: անգլերեն

source: Ministry of Health

active_ingredient:

LEVETIRACETAM 250 MG

MAH:

TEVA PHARMACEUTICAL INDUST.LTD

ATC_code:

N03AX14

pharmaceutical_form:

TABLETS

administration_route:

PER OS

manufactured_by:

TEVA PHARMACEUTICAL INDUSTRIES LTD

therapeutic_group:

LEVETIRACETAM

therapeutic_indication:

- Levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - Levetiracetam is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.- Levetiracetam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patient from 16 years of age with newly diagnosed epilepsy.- Levetiracetam is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

authorization_date:

2009-09-01